Imperial College London
Professor Robert Wilkinson

ProfessorRobertWilkinson

Faculty of Medicine, Department of Infectious Disease

Professor in Infectious Diseases
 
 
 
//

Contact

 

r.j.wilkinson Website

 
 
//

Location

 

Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Fendler:2021:10.1038/s43018-021-00275-9,
author = {Fendler, A and Au, L and Shepherd, STC and Byrne, F and Cerrone, M and Boos, LA and Rzeniewicz, K and Gordon, W and Shum, B and Gerard, CL and Ward, B and Xie, W and Schmitt, AM and Joharatnam-Hogan, N and Cornish, GH and Pule, M and Mekkaoui, L and Ng, KW and Carlyle, E and Edmonds, K and Del, Rosario L and Sarker, S and Lingard, K and Mangwende, M and Holt, L and Ahmod, H and Stone, R and Gomes, C and Flynn, HR and Agua-Doce, A and Hobson, P and Caidan, S and Howell, M and Wu, M and Goldstone, R and Crawford, M and Cubitt, L and Patel, H and Gavrielides, M and Nye, E and Snijders, AP and MacRae, J and Nicod, J and Gronthoud, F and Shea, RL and Messiou, C and Cunningham, D and Chau, I and Starling, N and Turner, N and Welsh, L and van, As N and Jones, RL and Droney, J and Banerjee, S and Tatham, KC and Jhanji, S and O'Brien, M and Curtis, O and Harrington, K and Bhide, S and Bazin, J and Robinson, A and Stephenson, C and Slattery, T and Khan, Y and Tippu, Z and Leslie, I and Gennatas,},
doi = {10.1038/s43018-021-00275-9},
journal = {Nature Cancer},
pages = {1321--1337},
title = {Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study},
url = {http://dx.doi.org/10.1038/s43018-021-00275-9},
volume = {2},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study, integrating longitudinal immune profiling with clinical annotation. Of 357 patients with cancer, 118 were SARS-CoV-2 positive, 94 were symptomatic and 2 died of COVID-19. In this cohort, 83% patients had S1-reactive antibodies and 82% had neutralizing antibodies against wild type SARS-CoV-2, whereas neutralizing antibody titers against the Alpha, Beta and Delta variants were substantially reduced. S1-reactive antibody levels decreased in 13% of patients, whereas neutralizing antibody titers remained stable for up to 329 days. Patients also had detectable SARS-CoV-2-specific T cells and CD4+ responses correlating with S1-reactive antibody levels, although patients with hematological malignancies had impaired immune responses that were disease and treatment specific, but presented compensatory cellular responses, further supported by clinical recovery in all but one patient. Overall, these findings advance the understanding of the nature and duration of the immune response to SARS-CoV-2 in patients with cancer.
AU  - Fendler,A
AU  - Au,L
AU  - Shepherd,STC
AU  - Byrne,F
AU  - Cerrone,M
AU  - Boos,LA
AU  - Rzeniewicz,K
AU  - Gordon,W
AU  - Shum,B
AU  - Gerard,CL
AU  - Ward,B
AU  - Xie,W
AU  - Schmitt,AM
AU  - Joharatnam-Hogan,N
AU  - Cornish,GH
AU  - Pule,M
AU  - Mekkaoui,L
AU  - Ng,KW
AU  - Carlyle,E
AU  - Edmonds,K
AU  - Del,Rosario L
AU  - Sarker,S
AU  - Lingard,K
AU  - Mangwende,M
AU  - Holt,L
AU  - Ahmod,H
AU  - Stone,R
AU  - Gomes,C
AU  - Flynn,HR
AU  - Agua-Doce,A
AU  - Hobson,P
AU  - Caidan,S
AU  - Howell,M
AU  - Wu,M
AU  - Goldstone,R
AU  - Crawford,M
AU  - Cubitt,L
AU  - Patel,H
AU  - Gavrielides,M
AU  - Nye,E
AU  - Snijders,AP
AU  - MacRae,J
AU  - Nicod,J
AU  - Gronthoud,F
AU  - Shea,RL
AU  - Messiou,C
AU  - Cunningham,D
AU  - Chau,I
AU  - Starling,N
AU  - Turner,N
AU  - Welsh,L
AU  - van,As N
AU  - Jones,RL
AU  - Droney,J
AU  - Banerjee,S
AU  - Tatham,KC
AU  - Jhanji,S
AU  - O'Brien,M
AU  - Curtis,O
AU  - Harrington,K
AU  - Bhide,S
AU  - Bazin,J
AU  - Robinson,A
AU  - Stephenson,C
AU  - Slattery,T
AU  - Khan,Y
AU  - Tippu,Z
AU  - Leslie,I
AU  - Gennatas,S
AU  - Okines,A
AU  - Reid,A
AU  - Young,K
AU  - Furness,AJS
AU  - Pickering,L
AU  - Gandhi,S
AU  - Gamblin,S
AU  - Swanton,C
AU  - Nicholson,E
AU  - Kumar,S
AU  - Yousaf,N
AU  - Wilkinson,KA
AU  - Swerdlow,A
AU  - Harvey,R
AU  - Kassiotis,G
AU  - Larkin,J
AU  - Wilkinson,RJ
AU  - Turajlic,S
DO  - 10.1038/s43018-021-00275-9
EP  - 1337
PY  - 2021///
SN  - 2662-1347
SP  - 1321
TI  - Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study
T2  - Nature Cancer
UR  - http://dx.doi.org/10.1038/s43018-021-00275-9
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000712508700002&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://www.nature.com/articles/s43018-021-00275-9
UR  - http://hdl.handle.net/10044/1/92957
VL  - 2
ER  -
Download